Monitor EASL data presentations (May 28-30) and the FDA Type-C meeting outcome; positive results could significantly de-risk belapectin and drive upside.
Price Chart
Executive Summary
Galectin Therapeutics reported Q1 2026 EPS of -$0.08, missing consensus of -$0.06 (-33.3% miss), but highlighted positive clinical data from its NAVIGATE trial and upcoming catalysts including EASL presentations and an FDA Type-C meeting. Despite the EPS miss, the clinical progress and upcoming milestones are the primary drivers for the stock.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.08 vs consensus -$0.06 (33.3% miss)
- Cash and equivalents of $14.1M as of March 31, 2026, plus $10M available line of credit
- Positive belapectin NAVIGATE data: statistically significant reduction in liver stiffness at Weeks 26, 52, and 78
- Upcoming catalysts: EASL presentations (May 28-30, 2026) and FDA Type-C meeting in Q2 2026
Financial Impact
EPS miss of $0.02 per share, net loss of $5.1M
Risk Factors
- Clinical trial and regulatory risk for belapectin
- EPS miss reflects ongoing R&D spending; dilution risk via line of credit
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295804 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | DEFA14A | $3.69 | awaiting T+20 | — | $3.19 (−13.55%) |
Oct 13, 2026 13d ago | DEF 14A | $3.69 | awaiting T+20 | — | $3.19 (+13.55%) |
Oct 6, 2026 20d ago | Press Release | $3.76 | awaiting T+20 | — | $3.19 (−15.16%) |
Aug 14, 2026 10w ago | Press Release | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.19 (−7.27%) |
Aug 14, 2026 10w ago | 8-K | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.19 (−7.27%) |
Aug 4, 2026 11w ago | 8-K | $2.99 $4.17 | ▲ +39.46% | ▲ +40.70% | $3.19 (+6.69%) |
Jun 30, 2026 16w ago | Insider Cluster | $4.33 $3.49 | ▼ −19.40% | ▼ −17.21% | $3.19 (−26.33%) |
May 15, 2026 23w ago | Press Release | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.19 (+47.00%) |
May 15, 2026 23w ago | 8-K | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.19 (+47.00%) |
Apr 13, 2026 28w ago | EFFECT | $2.35 $2.21 | ▼ −5.96% | ▼ −13.69% | $3.19 (+35.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers